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To investigate annexin-based optical fluorescence imaging (OI) for monitoring regorafenib-
induced early cell death in experimental colon carcinomas in rats, validated by perfusion
MRI and multiparametric immunohistochemistry.
Materials and Methods
Subcutaneous human colon carcinomas (HT-29) in athymic rats (n = 16) were imaged
before and after a one-week therapy with regorafenib (n = 8) or placebo (n = 8) using
annexin-based OI and perfusion MRI at 3 Tesla. Optical signal-to-noise ratio (SNR) and
MRI tumor perfusion parameters (plasma flow PF, mL/100mL/min; plasma volume PV, %)
were assessed. On day 7, tumors underwent immunohistochemical analysis for tumor cell
apoptosis (TUNEL), proliferation (Ki-67), and microvascular density (CD31).
Results
Apoptosis-targeted OI demonstrated a tumor-specific probe accumulation with a significant
increase of tumor SNR under therapy (mean Δ +7.78±2.95, control: -0.80±2.48, p = 0.021).
MRI detected a significant reduction of tumor perfusion in the therapy group (mean ΔPF
-8.17±2.32 mL/100 mL/min, control -0.11±3.36 mL/100 mL/min, p = 0.036). Immunohis-
tochemistry showed significantly more apoptosis (TUNEL; 11392±1486 vs. 2921±334, p =
0.001), significantly less proliferation (Ki-67; 1754±184 vs. 2883±323, p = 0.012), and
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significantly lower microvascular density (CD31; 107±10 vs. 182±22, p = 0.006) in the ther-
apy group.
Conclusions
Annexin-based OI allowed for the non-invasive monitoring of regorafenib-induced early cell
death in experimental colon carcinomas, validated by perfusion MRI and multiparametric
immunohistochemistry.
Introduction
The multityrosine kinase inhibitor (MTKI) regorafenib is one of the most recent treatment
options for patients with advanced colorectal cancer [1]. MTKI are a class of molecular agents
known to exhibit significant effects on tumor physiology with only minor effects on tumor
size, particularly in the early treatment phase [2]. Therefore, traditional, morphology-based
response evaluation criteria such as the Response Evaluation Criteria In Solid Tumors
(RECIST) are of limited value in MTKI-treated patients [3]. Recently, a decrease in tumor per-
fusion as assessed by DCE-CT or DCE-MRI has been proposed as a new imaging biomarker of
therapy response for the anti-angiogenic effects of MTKI [4–6].
Beyond functional imaging, the investigation of molecular imaging techniques may convey
a deeper understanding of tumor pathophysiology under therapy. Along with a significant sup-
pression of tumor microperfusion, regorafenib exhibits significant pro-apoptotic effects on
human colon carcinoma models [7–9]. Targeting the receptor tyrosine kinases vascular endo-
thelial growth factor receptor (VEGFR) 1 to 3, angiopoietin-1 receptor (TIE2), and platelet-
derived growth factor receptor (PDGFR) β, regorafenib inhibits tumor neovascularization and
vessel stabilization [10]. Its pro-apoptotic effects in colorectal cancer are mediated by induction
of p53-upregulated modulator of apoptosis (PUMA), leading to dysfunction of mitochondria
and caspase activation [7]. In addition, regorafenib has been shown to enhance SH2-domain-
containing phosphatase 1 (SHP-1) activity, leading to an inhibition of STAT3 and therefore
increasing apoptosis [11]. Thus, apoptosis is a promising target for the non-invasive characteri-
zation of the tumor microenviroment of experimental colon carcinomas under regorafenib
therapy in vivo. Near-infrared range (NIR) optical fluorescence imaging (OI) with targeted
probes is a preclinical molecular imaging modality allowing for the non-invasive visualization
of tumor cell apoptosis, generating real-time information on tumor pathophysiology which to
date can only be obtained by histopathological analysis ex vivo [12]. Hence, adding apoptosis-
targeted OI to a multiparametric MRI protocol would build a novel molecular hybrid imaging
concept for the real-time and non-invasive assessment of early therapy effects beyond the mor-
phological and functional level.
We hypothesized that a one-week regorafenib monotherapy would exhibit significant pro-
apoptotic effects on experimental colon carcinoma xenografts in rats as assessed by OI with an
apoptosis-targeted probe, validated by DCE-MRI and multiparametric immunohistochemistry.
The aim of the study was to investigate if apoptosis-targeted OI can provide information on
early therapy response of experimental colon carcinomas to MTKI therapy in vivo.
Materials and Methods
The trial received approval by the Government (Regierung von Oberbayern, Germany) Com-
mittee for Animal Research (Gz.: 55.2-1-54-2532-33-10). It was conducted in accordance with
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the guidelines of the National Institute of Health for the Care and Use of Laboratory Animals.
Animals were kept in individually-ventilated cage systems (n = 4 per cage) at a constant tem-
perature of 26°C, a relative humidity of 65%, and 18 room air changes per hour. The light-
dark-cycle was 12 hours. Animals were nourished ad libitum with water and dedicated small
animal nutrition. For environmental enrichment purposes, rat nest boxes were provided. Ani-
mals were euthanized under inhalation anesthesia (5.0% isoflurane in pure oxygen) by intra-
cardial injection of a saturated potassium chloride solution. Every effort was made in order to
avoid animal suffering.
Animal model and examination protocol
Athymic nude rats (n = 16, 7–8 weeks old, Harlan Laboratories Inc., Indianapolis, IN) were
subcutaneously injected with 3 × 106 cells of the human colon carcinoma cell line HT-29
(ATCC HTB-38) which were suspended in 0.5 mL of equal parts of Matrigel™ (BD Biosciences,
San Jose, CA) and phosphate buffered saline (PBS, pH 7.4). After reaching a tumor diameter
of 1.0 cm, animals were randomly assigned to either the therapy (n = 8) or the control group
(n = 8). Before initiation of treatment, both control and therapy group were scanned by
DCE-MRI and OI (day 0, baseline examination). MRI contrast agent and OI probe were
administered via intravenous tail vein catheter (butterfly catheter, 25-gauge, B. Braun AG, Mel-
sungen, Germany). The examinations were performed under inhalation anaesthesia (2.5% to
5.0% isoflurane in pure oxygen). The OI probe was injected 2 h prior to the OI scan as recom-
mended by the manufacturer and as confirmed by preliminary kinetic studies. In the mean-
time, animals were transferred to the MRI suite where DCE-MRI measurements were
performed. Immediately after the MRI scan, the animals were transferred to the laboratory
where the OI scan was performed. Detailed imaging protocols for DCE-MRI and OI are pro-
vided below. From day 1 to 6, animals were treated with either regorafenib (therapy group) or
placebo (control group). On day 7, the multimodality DCE-MRI/OI imaging protocol was
repeated as described above (follow-up examination). After euthanization of the animals on
day 7 and subsequent tumor explantation, the tumor material was fixed in formalin for immu-
nohistochemical analysis.
Treatment
Regorafenib was solved in polypropylene glycol/PEG400/Poloxamer 188 (42.5/42.5/15 + 20%
Aqua). The therapy group was treated with a daily dose of 10 mg regorafenib per kg body
weight via gastric gavage while the control group received a volume-equivalent placebo.
OI protocol
OI was performed on a fully automated preclinical small animal optical imaging system (In-
Vivo FX PRO, Bruker Corp., Billerica, MA) using a charge-coupled device (CCD) camera
(2048 x 2048 pixels). The commercially available apoptosis-targeted probe Annexin Vivo 750
(Perkin Elmer, Waltham, MA) was injected manually via the lateral tail vein at a dose of 16
nmol, according to the manufacturer’s recommendation. Preliminary kinetic studies demon-
strated that peak intra-tumor annexin accumulation was 2 h after intravenous injection, con-
firming the manufacturer’s recommendation. Annexin Vivo 750 is built of a NIR
fluorochrome conjugated to Annexin A5, a cellular protein selectively binding to phosphatidyl-
serine which is expressed on the phospholipid bilayers of cell membranes during the early
stages of apoptosis [13]. According to the manufacturer, tissue half-life time of Annexin Vivo
750 is 14 h. Naïve scans documented full tumor clearance of the probe after a follow-up period
of one week. Residual fur of the athymic nude rats was removed in a dedicated depilatory
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procedure in order to avoid scattering and absorption artifacts [14]. Animals were scanned in
the lateral position with the subcutaneous tumor placed directly on the examination plane. In
pilot fluorescence studies, an optimal SNR was delivered at an imaging time of 30 s. The com-
prehensive multi-step optical imaging protocol consisted of an x-ray (step 1, exposure time
1 s), a white-light (step 2, excitation filter 410 nm, no emission filter, field-of-view 200.0 mm,
focal plane 11.0 mm, f/2.5, resolution 260 ppi x 260 ppi, exposure time 1 s), and a fluorescence
scan (step 3, excitation filter 730 nm, emission filter 790 nm, field-of-view 200.0 mm, focal
plane 11.0 mm, 2x x-binning, 2x y-binning, resolution 130 ppi x 130 ppi, exposure time 30 s),
with a total scan duration of 7 min. A naïve scan was performed for the differentiation of signal
from background noise.
OI data and image analysis
Using dedicated molecular imaging post-processing software (Bruker Molecular Imaging Soft-
ware, Bruker Corp., Billerica, MA), a region of interest (ROI) was placed over the tumor (target
tissue), the thigh muscle (non-target tissue), and the background beside the mouse. OI signal-
to-noise ratio (SNR) was calculated using a formula published previously [15], where SI is the
mean signal intensity normalized for tumor area and SD the standard deviation of the back-
ground noise within a defined ROI: SNR = (SItumor−SInon-target tissue)/SDbackground. Signal inten-
sity was expressed as arbitrary units [a.u.].
DCE-MRI
MRI examinations were performed on a clinical 3 Tesla scanner (Magnetom Verio, Siemens
Healthcare, Erlangen, Germany). Animals were examined in supine position using a four-
channel small-animal coil (Rapid MR International, Columbus, OH). The clinical low molecu-
lar contrast agent Gadobutrol (Gadovist1, Bayer HealthCare, Leverkusen, Germany) was
administered intravenously by a dedicated automated small-animal injection pump (Harvard
Apparatus PHD 2000, Instech Lab. Inc., Plymouth Meeting, PA) at a dose of 0.1 mmol/kg
body weight with an injection speed of 7.2 mL/min and a subsequent 0.5 mL saline chaser. A
3D view-sharing sequence (Time-Resolved Angiography With Stochastic Trajectories, TWIST,
Siemens Healthcare, Erlangen, Germany; temporal resolution 1.3 s) was performed for assess-
ment of tumor contrast kinetics. After acquisition of 10 non-enhanced frames within 13 s, 290
additional contrast-enhanced frames were obtained. The protocol rendered 300 high-resolu-
tion 3D data sets. Sequence parameter were as follows: spatial resolution 0.39 mm x 0.39 mm x
3.0 mm, repetition time/echo time 6.34/2.11 ms, 128 x 128 matrix, field-of-view 50 mm x
50 mm, flip angle 40°, total acquisition time 6:30 min).
MRI Data Processing–kinetic analysis
Data post-processing was performed on a PMI (Platform for Research in Medical Imaging)
workstation, with software written in-house in IDL 6.4 (ITT Visual Information Solutions,
Boulder, CO). To generate an arterial input function (AIF), a blood ROI was placed over the
inferior vena cava at the level of the liver. The tumor ROI was placed over the tumor periphery,
defined as the outer 2 mm of the tumor in which high interstitial pressure and necrosis are less
likely to occur [4]. Signal intensity was plotted versus time for the approximation of probe con-
centrations in relation to their relative enhancement. Fitting the data to a two-compartment
uptake model allowed for the calculation of plasma flow (PF, mL/100 mL/min, surrogate of
tumor perfusion) and plasma volume (PV, %, surrogate of tumor vascularity). For assessments
of tumor sizes pre and post therapy, a voxel-based volumetry was performed.
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Immunohistochemistry
Tissue samples fixed in formaldehyde and embedded in paraffin were heated to 60°C and
washed in xylene substitute (Neo-Clear, Merck KgaA, Darmstadt, Germany) for de-waxing,
then re-hydrated in ethanol at different concentrations (100%, 96%, 90%, 70%) and distilled
water. Subsequent to tissue demasking by microwave irradiation at 600 W in a 0.1 M citrate
buffer solution (pH 6.0), dedicated staining was performed with regard to microvascular den-
sity (CD31), tumor cell proliferation (Ki-67), and tumor cell apoptosis (Terminal Deoxynu-
cleotidyl Transferase-mediated Nick End Labeling, TUNEL). Results were expressed as the
average number of positively-stained structures in 10 random fields at a magnification of 200x.
CD31. Tissue demasking was performed in a 0.1 M citrate buffer solution with microwave
irradiation at 600 W. Following overnight incubation with the primary antibody (ab28364,
1:50), a commercially available kit (EnVision+ System HRP (AEC), Dako, Germany) was
applied for further work-up.
Ki-67. Tissue demasking was performed in a 0.1 M citrate buffer solution with microwave
irradiation at 600 W. Tumor cell proliferation was quantified by a monoclonal rabbit anti-rat
antibody specific for Ki-67. For permeabilization purposes, slides were immersed in 0.25% Tri-
ton X-100 –Tris-Cl solution. A commercial multi-step kit (Dako EnVision+ HRP (DAB),
Dako, Germany) was employed for secondary antibody application to the primary antibody
(ab16667, 1:100).
TUNEL. Tissue samples were prepared using a dedicated apoptosis detection kit (in situ
Cell Death Detection Kit, Roche Diagnostics, Indianapolis, IN) and subsequently analyzed by
fluorescence microscopy (standard fluorescent filter, 520±20 nm).
Statistical Analysis
Outcome parameters were SNR (OI), PF (mL/100 mL/min, DCE-MRI), PV (%, DCE-MRI),
and the positively-stained structures per high-power field (immunohistochemistry), expressed
as means with standard errors (SE). The parameters were also expressed as differences (Δ) of
post minus pre therapy values (ΔSNR, ΔPF, ΔPV). For intra- and inter-group comparisons, a
Wilcoxon signed-rank test was applied. Correlations between imaging and immunohistochem-
ical parameters were assessed by Spearman’s rho. Statistical significance was assumed for p-val-
ues<0.05.
Results
Measurements were successfully completed in 16 animals (therapy group, n = 8; control group,
n = 8).
Optical fluorescence imaging
There was no significant difference in pre-treatment values between therapy and control group
(mean pre-treatment SNR: therapy group 27.6 ± 4.7, control group 26.3 ± 1.6, p = 0.401).
Regorafenib therapy lead to a significant, unidirectional increase of absolute SNR between
baseline and follow-up (mean SNR from 27.6 ± 4.7 to 35.3 ± 5.9; p = 0.012). On the contrary,
absolute SNR values developed heterogeneously and non-significantly in the control group
(mean SNR from 26.3 ± 1.6 to 25.5 ± 3.1, p = 0.674). A significant difference in ΔSNR between
therapy and control group was observed (mean ΔSNR: therapy group +7.8 ± 2.9, control group
-0.8 ± 2.5, p = 0.021). Fig 1 shows the increase of annexin-related OI signal under regorafenib
therapy in one animal (Fig 1). High signal intensity was also observed in the kidney and the uri-
nary bladder due to renal probe elimination. Accordingly, ex vivo OI analysis of the main
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organs revealed highest probe accumulation in the tumor and the kidneys (Fig 2). See Tables 1
and 2 for individual OI values pre and post treatment, also displayed as line graphs in Fig 3.
Perfusion MRI
No significant difference in pre-treatment plasma flow values between therapy and control
group was observed (mean pre-treatment PF: therapy group 18.3 ± 2.5 mL/100 mL/min, con-
trol group 14.3 ± 3.3 mL/100 mL/min, p = 0.172). Under therapy, a significant, unidirectional
suppression of PF was detected between day 0 and day 7 (mean PF: baseline 18.3 ± 2.5 mL/
100 mL/min, follow-up 10.2 ± 1.6 mL/100 mL/min, p = 0.012). No significant change in PF
between baseline and follow-up was observed in the control group (mean PF: baseline
14.3 ± 3.3 mL/100 mL/min, follow-up 14.2 ± 1.4 mL/100 mL/min, p = 0.674). ΔPF differed sig-
nificantly between therapy and control group, showing a significant suppression of tumor per-
fusion under therapy (mean ΔPF: therapy group –8.2 ± 2.3 mL/100 mL/min, control group –
0.1 ± 3.4 mL/100 mL/min, p = 0.036). No statistically significant effects were observed on PV.
Fig 4 shows an example of tumor PF suppression in one animal from the therapy group (Fig 4).
Individual values of PF in the therapy and the control group are displayed in Tables 1 and 2
and as line graphs in Fig 3.
Immunohistochemistry
Immunohistochemical analysis revealed a significantly higher rate of apoptosis in the regorafe-
nib-treated group (mean number of cells stained positive for TUNEL: therapy group
11392 ± 1486, control group 2921 ± 334, p = 0.001). Likewise, a significant suppression of
tumor cell proliferation (mean number of cells stained positive for Ki-67: therapy group
1754 ± 184, control group 2883 ± 323, p = 0.012) and tumor vascularity (mean number of cells
stained positive for CD31: therapy group 107 ± 10, control group 182 ± 22, p = 0.006) was
observed. Individual values for the immunohistochemical parameters are provided in Table 3.
Fig 5 displays representative immunohistochemical stainings of one tumor from the therapy
group.
Fig 1. Cell death-related OI signal before and after treatment. Fusion of color-coded fluorescence and
anatomic white-light image of one animal before (A) and after (B) a one-week regorafenib monotherapy. Note
the significant increase in cell death-related signal under therapy, predominantly in the center of the tumor.
High signal intensity is also observed in the kidneys and the urinary bladder due to renal probe elimination. OI
signal intensity (SI) is displayed in arbitrary units (a.u.).
doi:10.1371/journal.pone.0138452.g001
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Tumor sizes in treatment and control group
We did not observe any significant differences in initial tumor size between the two groups
(therapy group 881±361cm3, control group 669±79 cm3; p = 0.6). No correlation between
changes in tumor volume pre/post therapy and OI SNR were observed (Spearman’s rho -0.115,
p = 0.672).
Correlations between non-invasive imaging biomarkers and
immunohistochemistry
We observed a significant inverse correlation between OIdiff and proliferation as assessed by
Ki-67 (Spearman’s rho -0.538, p = 0.031). OIdiff also showed a moderate but not significant
positive correlation with apoptosis assessed by TUNEL (Spearman’s rho 0.385, p = 0.141). An
Fig 2. Ex vivoOI analysis of explantedmain organs. Fusion of color-coded fluorescence and anatomic white-light image. In accordance with the in vivo
results, highest OI signal is observed in the kidneys (1) and the tumor (2) (red arrows). As a blood pool organ, the spleen (3) demonstrates relatively high
probe accumulation. Only subtle OI signal is detected in the gut (4), the skin (5), and the thigh muscle (6). OI signal intensity (SI) is displayed in arbitrary units
(a.u.).
doi:10.1371/journal.pone.0138452.g002
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inverse correlation of OIdiff and PFdiff was observed which proved borderline-significant
(Spearman’s rho -0.474, p = 0.064). No other significant correlations were observed.
Discussion
In this experimental study, OI with fluorescence-labeled Annexin A5 was investigated in a
human colon carcinoma model in rats. Annexin-based OI allowed for the non-invasive visuali-
zation and quantification of early cell death induced by a regorafenib monotherapy in vivo, as
validated by DCE-MRI and multiparametric immunohistochemistry.
Optical Fluorescence Imaging
Annexin-based OI generated non-invasive surrogates of regorafenib-induced tumor cell death
in vivo as validated by dedicated immunohistochemistry (TUNEL). These findings are in line
Table 1. Individual OI and MR perfusion values at baseline and follow-up (therapy group). Note the significant increase of apoptosis-targeted OI signal
and the significant plasma flow (PF) reduction in the therapy group (p < 0.05).
Animal no. aOI bOI* aPF bPF* aPV bPV
1 48.3 64.5 34.7 14.5 10.1 8.7
2 48.5 50.2 13.2 2.5 5.4 4.6
3 21.4 46.2 12.9 9.8 19.9 10.6
4 20.6 24.8 18.0 15.0 7.3 3.2
5 20.0 20.6 14.8 8.7 19.6 7.8
6 18.4 23.1 14.4 9.8 22.6 11.7
7 15.1 19.5 21.6 6.4 6.9 9.7
8 28.3 33.9 17.0 14.6 14.0 13.9
mean 27.6 35.3 18.3 10.2 13.2 8.8
SE 4.8 5.9 2.6 1.6 2.4 1.3
abaseline
bfollow-up; SE = standard error
*p < 0.05 (follow-up vs. baseline)
doi:10.1371/journal.pone.0138452.t001
Table 2. Individual OI and MR perfusion values at baseline and follow-up (control group). Note the omnidirectional development of individual apopto-
sis-targeted OI signal and perfusion parameters.
Animal no. aOI bOI aPF bPF aPV bPV
9 35.4 35.3 34.8 15.1 8.0 15.8
10 23.0 26.8 7.0 13.6 17.4 7.9
11 28.9 40.1 17.9 9.0 7.6 4.7
12 25.2 27.5 9.6 16.4 8.2 20.4
13 24.9 20.6 7.9 10.7 9.5 14.0
14 20.3 20.1 8.3 10.5 9.0 8.7
15 25.8 14.9 10.6 18.5 23.8 35.6
16 26.8 18.6 18.5 19.9 10.7 8.8
mean 26.3 25.5 14.3 14.2 11.8 14.5
SE 1.6 3.0 3.3 1.4 2.1 3.5
abaseline
bfollow-up; SE = standard error
*p < 0.05 (follow-up vs. baseline)
doi:10.1371/journal.pone.0138452.t002
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with trials investigating annexin-based OI probes for the monitoring of cytotoxic and epider-
mal growth factor receptor (EGFR)-targeted therapies in vivo [16,17]. Additionally, they are in
accordance with recent studies demonstrating that radiolabeled Annexin A5 allows for the in
vivo monitoring of cell death in experimental lung cancer treated by cytotoxic therapy as well
as in animal models of myocardial infarction [18,19]. Our results provide evidence for the
applicability of fluorescence-labeled Annexin A5 for the monitoring of anti-angiogenic therapy
regimes in vivo.
Contrarily, in a recent preclinical study investigating early therapy effects of MTKI sunitinib
in a human squamous cell carcinoma model in mice, annexin-based optical and gamma imag-
ing failed to detect early pro-apoptotic therapy effects [20]. The authors concluded that
annexin-based imaging was not suitable for monitoring effects of anti-angiogenic therapies
leading to a substantial breakdown of tumor vasculature, as consecutively the probe would not
be delivered to the tumor microenvironment. According to this conclusion, one would expect a
reduced annexin-related signal after anti-angiogenic treatment. However, we found a signifi-
cant increase of annexin-related signal in the therapy group, making unspecific accumulation
of the probe unlikely. Another possible explanation for the divergent findings in our study may
Fig 3. Development of individual OI and MR perfusion values. Line graphs depicting development of individual optical fluorescence imaging (OI, SNR)
and plasma flow (PF, mL/100 mL/min) values between baseline and follow-up. Note the unidirectional increase of OI SNR (A) and the unidirectional
suppression of PF (C) under therapy. On the contrary, omnidirectional development of individual OI SNR (B) and PF (D) was observed in the control group.
doi:10.1371/journal.pone.0138452.g003
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be the longer follow-up interval of seven vs. four days, which may allow for a partial reforma-
tion and normalization of tumor microvasculature. Additionally, applicability of NIR agents as
well as vascular responsiveness to anti-angiogenic treatment may vary between different tumor
Fig 4. Decrease of tumor perfusion following anti-angiogenic therapy. Tumor perfusion (Plasma Flow, PF) before (A) and after (B) a one-week
regorafenib treatment of a subcutaneous colon carcinoma xenografts over the left abdominal flank. Note the significantly reduced plasma flow after therapy
(B vs. A).
doi:10.1371/journal.pone.0138452.g004
Table 3. Individual immunohistochemical values in the control (animals no. 1 to 8) and the therapy
group (animals no. 9 to 16). Note the significantly lower microvascular density (CD31) and proliferation (Ki-
67) as well as the significantly higher apoptosis rate in the therapy group (p < 0.05).
Animal no. CD31 TUNEL Ki-67
1 203 2020 2699
2 162 2902 2488
3 282 2551 3821
4 124 2269 1975
5 174 2206 3204
6 136 4923 1566
7 114 3514 4331
8 261 2982 2982
Mean 182 2921 2883
SE 22 334 323
9 144 6239 1299
10 79 7614 1336
11 101 8010 1639
12 160 10791 2245
13 98 18505 2536
14 85 11983 1458
15 100 15762 2293
16 93 12301 1233
Mean 107* 11392* 1754*
SE 10 1486 184
SE = standard error
*p < 0.05 (control vs. therapy group)
doi:10.1371/journal.pone.0138452.t003
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models. For instance, NIR blood pool agents detected early anti-angiogenic effects of sunitinib
in experimental squamous cell carcinomas, but failed to show treatment-induced vascular
changes in experimental breast carcinomas, although significant anti-angiogenic effects were
proven by DCE-MRI, CEUS, and immunohistochemistry [20,21].
Our results suggest that annexin-based is able to generate non-invasive and real-time
molecular data on tumor cell death in vivo. However, several issues remain to be addressed
before OI can be translated into clinical routine.
Clinical limitations of OI. One major limitation of OI is the low penetration depth of
only several centimeters [22], restricting the use to superficially-located structures. Several
techniques for the direct on-surface application of OI have been established, including trans-
catheter, cystoscopic, endoscopic, and laparoscopic approaches [22–25]. Moreover, intraopera-
tive OI has been applied successfully for the differentiation of healthy and tumor-invaded
brain tissue [26–28]. Likewise, as regorafenib has been granted approval for the treatment of
advanced colorectal carcinoma (i.e., hepatic metastazisation), one would have to find a similar
way to successfully apply OI in the upper abdomen [29], where overlaying bones (i.e., ribs) and
respiratory motion artifacts during the relatively long acquisition time may additionally com-
promise the clinical applicability.
Limitations of annexin-based imaging. Annexin A5 is known for its unspecific binding
to abdominal organs and its slow tissue clearance, resulting in high background noise
Fig 5. Representative immunohistochemical stainings. Tumor cell apoptosis (TUNEL, A and B), tumor
microvascular density (CD31, C and D), and tumor cell proliferation (Ki-67, E and F) in the control (left
column; A, C, and E) and the therapy group (right column; B, D, and F). Note the significantly higher
apoptosis rate (B vs. A) as well as the significantly lower microvascular density (D vs. C) and proliferation (F
vs. E) in the therapy group.
doi:10.1371/journal.pone.0138452.g005
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[13,30,31]. Ex vivo analysis confirmed this limitation (Fig 2). However, this may be excluded
by unenhanced scans prior to probe administration, as performed in the present study. Despite,
Annexin A5 is not immunogenic and has already been used clinically in radiolabeled PET trac-
ers, factors facilitating clinical translation of annexin-based OI probes [13,31].
Depending on the phagocytic activity of auxiliary scavenger cells, apoptosis may be suc-
ceeded by autolysis, i.e., secondary necrosis [32]. During secondary necrosis with consecutive
loss of cell membrane integrity, primarily intramembraneous phosphatidylserine is external-
ized and may thus be bound by Annexin A5. Consequently, annexin-based imaging is limited
in its ability to distinguish between apoptosis and necrosis; however, it can still be considered
an accurate measure of cell death. Several immunohistochemical techniques have been pro-
posed for the differentiation of apoptosis from secondary necrosis ex vivo, e.g., using propi-
dium iodide and necrostatin [33,34]. The applicability and additional value of these agents as
part of a multimodal, fluorescence-based imaging protocol for the assessment of therapy-
induced cell death in vivo should be investigated in future studies.
Perfusion MRI
DCE-MRI allowed for the timely and non-invasive assessment of regorafenib-induced suppres-
sion of tumor perfusion in the therapy group, supporting recent data stating similar effects in
an orthotopic colon carcinoma model in mice [9].
Immunohistochemistry
Immunohistochemical results are in accordance with recent preclinical trials investigating
regorafenib effects on a molecular level, demonstrating a significant reduction of microvascular
density and proliferation under therapy [7–9,35]. Most strikingly, there is wide evidence that
regorafenib acts as potent inductor of apoptosis, indicated by dedicated stainings for tumor cell
apoptosis (TUNEL), analogously to the present study [7–9].
Limitations
The results of our study are limited in several aspects. First, an orthotopic tumor model may
represent the pathophysiology of human cancer better and may potentially allow for the addi-
tional in vivo assessment of metastasis formation. Second, a broader range of immunohisto-
chemical markers may supply additional data with regard to the molecular effects of
regorafenib on the tumor microenvironment. Third, only one combination of a tumor model
and a molecular cancer therapy has been investigated, and imaging has only been performed
after a follow-up time of seven days.
Conclusions
In conclusion, annexin-based OI allowed for the early and non-invasive monitoring of a regor-
afenib monotherapy in experimental colon carcinomas in rats, as validated by perfusion MRI
and multiparametric immunohistochemistry. Thus, annexin-based OI may be applied for the
non-invasive characterization of early tumor cell death under therapy in vivo. Combining mor-
phology-based, functional, and molecular imaging techniques, future multimodality imaging
protocols may facilitate patient assignment to targeted cancer therapies by the timely and non-
invasive differentiation of responders and non-responders.
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